Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2012, Article ID 673631, 20 pages
http://dx.doi.org/10.1155/2012/673631
Review Article

Pre-, Pro-, and Synbiotics: Do They Have a Role in Reducing Uremic Toxins? A Systematic Review and Meta-Analysis

1School of Medicine, The University of Queensland, Brisbane, QLD 4006, Australia
2Department of Nutrition and Dietetics, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia
3Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia
4Queensland Clinical Trials & Biostatistics Centre, School of Population Health, The University of Queensland, Brisbane, QLD 4006, Australia

Received 20 July 2012; Accepted 29 August 2012

Academic Editor: Siren Sezer

Copyright © 2012 Megan Rossi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organisation, The Global Burden of Disease: 2004 Update, WHO Press, Geneva, Switzerland, 2004.
  2. D. E. Weiner, H. Tighiouart, M. G. Amin et al., “Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies,” Journal of the American Society of Nephrology, vol. 15, no. 5, pp. 1307–1315, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Schepers, G. Glorieux, and R. Vanholder, “The gut: the forgotten organ in Uremia?” Blood Purification, vol. 29, no. 2, pp. 130–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. B. K. I. Meijers, H. De Loor, B. Bammens, K. Verbeke, Y. Vanrenterghem, and P. Evenepoel, “p-cresyl sulfate and indoxyl sulfate in hemodialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 12, pp. 1932–1938, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Taki, Y. Tsuruta, and T. Niwa, “Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients,” American Journal of Nephrology, vol. 27, no. 1, pp. 30–35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Niwa, “Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120,” Therapeutic Apheresis and Dialysis, vol. 15, no. 2, pp. 120–124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. B. K. I. Meijers and P. Evenepoel, “The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression,” Nephrology Dialysis Transplantation, vol. 26, no. 3, pp. 759–761, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Evenepoel, B. K. I. Meijers, B. R. M. Bammens, and K. Verbeke, “Uremic toxins originating from colonic microbial metabolism,” Kidney International, vol. 76, supplement 114, pp. S12–S19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Evenepoel, D. Claus, B. Geypens et al., “Amount and fate of egg protein escaping assimilation in the small intestine of humans,” American Journal of Physiology, vol. 277, no. 5, pp. G935–G943, 1999. View at Google Scholar · View at Scopus
  10. C. J. Lin, H. H. Chen, C. F. Pan et al., “p-cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease,” Journal of Clinical Laboratory Analysis, vol. 25, no. 3, pp. 191–197, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Gibson, K. Scott, and R. Rastall, “Dietary Prebitoics: current status and new defintion,” IFIS Functional Foods Bulletin, vol. 7, no. 1, pp. 1–19, 2010. View at Publisher · View at Google Scholar
  12. National Health and Medical Research Council Guideline Assessment Register Consultants, NHMRC Levels of Evidence and Grades for Recommendations for Developers of Guidelines, N.H.A.M.R. Council, 2009.
  13. K. Uhlig, A. MacLeod, J. Craig et al., “Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO),” Kidney International, vol. 70, no. 12, pp. 2058–2065, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. D. S. Wishart, D. Tzur, C. Knox et al., Human Metabolome Database, Genome Alberta & Genome, Canada, 2009.
  15. R. Vanholder, B. Bammens, H. De Loor et al., “Warning: the unfortunate end of p-cresol as a uraemic toxin,” Nephrology Dialysis Transplantation, vol. 26, no. 5, pp. 1464–1467, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. R Development Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, 2011.
  17. W. Viechtbauer, “Conducting meta-analyses in R with the metafor,” Journal of Statistical Software, vol. 36, no. 3, pp. 1–48, 2010. View at Google Scholar · View at Scopus
  18. L. Cloetens, W. F. Broekaert, Y. Delaedt et al., “Tolerance of arabinoxylan-oligosaccharides and their prebiotic activity in healthy subjects: a randomised, placebo-controlled cross-over study,” British Journal of Nutrition, vol. 103, no. 5, pp. 703–713, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. V. De Preter, T. Vanhoutte, G. Huys, J. Swings, P. Rutgeerts, and K. Verbeke, “Baseline microbiota activity and initial bifidobacteria counts influence responses to prebiotic dosing in healthy subjects,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 6, pp. 504–513, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Ito, M. Kimura, Y. Deguchi, A. Miyamori-Watabe, T. Yajima, and T. Kan, “Effects of transgalactosylated disaccharides on the human intestinal microflora and their metabolism,” Journal of Nutritional Science and Vitaminology, vol. 39, no. 3, pp. 279–288, 1993. View at Publisher · View at Google Scholar
  21. M. Ito, Y. Deguchi, K. Matsumoto, M. Kimura, N. Onodera, and T. Yajima, “Influence of galactooligosaccharides on the human fecal microflora,” Journal of Nutritional Science and Vitaminology, vol. 39, no. 6, pp. 635–640, 1993. View at Publisher · View at Google Scholar
  22. A. Terada, H. Hara, M. Kataoka, and T. Mitsuoka, “Effect of lactulose on the composition and Metabolic Activity of the Human Faecal Flora,” Microbial Ecology in Health and Disease, vol. 5, no. 1, pp. 43–50, 1992. View at Google Scholar
  23. K. P. Geboes, G. De Hertogh, V. De Preter et al., “The influence of inulin on the absorption of nitrogen and the production of metabolites of protein fermentation in the colon,” British Journal of Nutrition, vol. 96, no. 6, pp. 1078–1086, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. M. S. Alles, R. Hartemink, S. Meyboom et al., “Effect of transgalactooligosaccharides on the composition of the human intestinal microflora and on putative risk markers for colon cancer,” American Journal of Clinical Nutrition, vol. 69, no. 5, pp. 980–991, 1999. View at Google Scholar · View at Scopus
  25. W. H. Ling, R. Korpela, H. Mykkanen, S. Salminen, and O. Hanninen, “Lactobacillus strain GG supplementation decreases colonic hydrolytic and reductive enzyme activities in healthy female adults,” Journal of Nutrition, vol. 124, no. 1, pp. 18–23, 1994. View at Google Scholar · View at Scopus
  26. K. Tohyama, Y. Kobayashi, and T. Kan, “Effect of lactobacilli on urinary indican excretion in gnotobiotic rats and in man,” Microbiology and Immunology, vol. 25, no. 2, pp. 101–112, 1981. View at Google Scholar · View at Scopus
  27. S. Fujiwara, Y. Seto, A. Kimura, and H. Hashiba, “Establishment of orally-administered Lactobacillus gasseri SBT2055SR in the gastrointestinal tract of humans and its influence on intestinal microflora and metabolism,” Journal of Applied Microbiology, vol. 90, no. 3, pp. 343–352, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. V. De Preter, T. Coopmans, P. Rutgeerts, and K. Verbeke, “Influence of long-term administration of lactulose and Saccharomyces boulardii on the colonic generation of phenolic compounds in healthy human subjects,” Journal of the American College of Nutrition, vol. 25, no. 6, pp. 541–549, 2006. View at Google Scholar · View at Scopus
  29. V. De Preter, K. Geboes, K. Verbrugghe et al., “The in vivo use of the stable isotope-labelled biomarkers lactose-[15N]ureide and [2H4]tyrosine to assess the effects of pro- and prebiotics on the intestinal flora of healthy human volunteers,” British Journal of Nutrition, vol. 92, no. 3, pp. 439–446, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. V. De Preter, T. Vanhoutte, G. Huys et al., “Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans,” American Journal of Physiology, vol. 292, no. 1, pp. G358–G368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. K. S. Swanson, C. M. Grieshop, E. A. Flickinger et al., “Fructooligosaccharides and Lactobacillus acidophilus modify bowel function and protein catabolites excreted by healthy humans,” Journal of Nutrition, vol. 132, no. 10, pp. 3042–3050, 2002. View at Google Scholar · View at Scopus
  32. B. K. I. Meijers, V. De Preter, K. Verbeke, Y. Vanrenterghem, and P. Evenepoel, “P-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin,” Nephrology Dialysis Transplantation, vol. 25, no. 1, pp. 219–224, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Takayama, K. Taki, and T. Niwa, “Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis,” American Journal of Kidney Diseases, vol. 41, no. 3, pp. S142–S145, 2003. View at Google Scholar · View at Scopus
  34. K. Taki, F. Takayama, and T. Niwa, “Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients,” Journal of Renal Nutrition, vol. 15, no. 1, pp. 77–80, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Hida, Y. Aiba, S. Sawamura, N. Suzuki, T. Satoh, and Y. Koga, “Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oval administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis,” Nephron, vol. 74, no. 2, pp. 349–355, 1996. View at Google Scholar · View at Scopus
  36. I. Nakabayashi, M. Nakamura, K. Kawakami et al., “Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study,” Nephrology Dialysis Transplantation, vol. 26, no. 3, pp. 1094–1098, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Bammens, P. Evenepoel, K. Verbeke, and Y. Vanrenterghem, “Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept,” American Journal of Clinical Nutrition, vol. 80, no. 6, pp. 1536–1543, 2004. View at Google Scholar · View at Scopus
  38. B. Bammens, K. Verbeke, Y. Vanrenterghem, and P. Evenepoel, “Evidence for impaired assimilation of protein in chronic renal failure,” Kidney International, vol. 64, no. 6, pp. 2196–2203, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. J. H. Cummings, M. J. Hill, and E. S. Bone, “The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine,” American Journal of Clinical Nutrition, vol. 32, no. 10, pp. 2094–2101, 1979. View at Google Scholar · View at Scopus
  40. B. Geypens, D. Claus, P. Evenepoel et al., “Influence of dietary protein supplements on the formation of bacterial metabolites in the colon,” Gut, vol. 41, no. 1, pp. 70–76, 1997. View at Google Scholar · View at Scopus
  41. W. H. Ling and O. Hanninen, “Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans,” Journal of Nutrition, vol. 122, no. 4, pp. 924–930, 1992. View at Google Scholar · View at Scopus
  42. C. T. Lee, C. C. Kuo, Y. M. Chen et al., “Factors associated with blood concentrations of Indoxyl sulfate and p-Cresol in patients undergoing peritoneal dialysis,” Peritoneal Dialysis International, vol. 30, no. 4, pp. 456–463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Vitetta and A. Sali, “Probiotics, prebiotics and gastrointestinal health,” Medicine Today, vol. 9, no. 9, pp. 65–70, 2008. View at Google Scholar · View at Scopus
  44. D. Sutton, S. Dumbleton, and C. Allaway, “Can increased dietary fibre reduce laxative requirement in peritoneal dialysis patients?” Journal of Renal Care, vol. 33, no. 4, pp. 174–178, 2007. View at Google Scholar · View at Scopus
  45. H. F. Wang, P. S. Lim, M. D. Kao, E. C. Chan, L. C. Lin, and N. P. Wang, “Use of isomalto-oligosaccharide in the treatment of lipid profiles and constipation in hemodialysis patients,” Journal of Renal Nutrition, vol. 11, no. 2, pp. 73–79, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Den Hond, B. Geypens, and Y. Ghoos, “Effect of high performance chicory inulin on constipation,” Nutrition Research, vol. 20, no. 5, pp. 731–736, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. C. M. Hasler, “Functional foods: their role in disease prevention and health promotion,” Food Technology, vol. 52, no. 11, pp. 63–70, 1998. View at Google Scholar · View at Scopus
  48. K. L. Campbell, S. Ash, J. D. Bauer, and P. S. W. Davies, “Evaluation of nutrition assessment tools compared with body cell mass for the assessment of malnutrition in chronic kidney disease,” Journal of Renal Nutrition, vol. 17, no. 3, pp. 189–195, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. O. Heimbürger, A. R. Qureshi, W. S. Blaner, L. Berglund, and P. Stenvinkel, “Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy,” American Journal of Kidney Diseases, vol. 36, no. 6, pp. 1213–1225, 2000. View at Google Scholar · View at Scopus
  50. K. Campbell, K. Campbellm, H. MacLaughlin et al., “Evidence based practice guidelines for the nutritional management of chronic kidney disease,” Nutrition & Dietetics, vol. 63, supplement 2, pp. S33–S45, 2007. View at Google Scholar
  51. Mitsubishi Tanabe Pharma Corporation, A Study of AST-120 For Evaluating Prevention of Progression in Chronic Kidney Disease (EPPIC-1), 2011.
  52. T. Nakamura, Y. Kawagoe, T. Matsuda et al., “Oral adsorbent AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure,” Kidney and Blood Pressure Research, vol. 27, no. 2, pp. 121–126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Yu, Y. J. Kim, and D. H. Kang, “Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 1, pp. 30–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Sanaka, T. Akizawa, K. Koide, and S. Koshikawa, “Clinical analysis of renoprotective responding patients administrated with oral adsorbent in chronic renal failure secondary to chronic glomerulonephritis,” Therapeutic Apheresis, vol. 7, no. 2, pp. 269–278, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Ueda, N. Shibahara, S. Takagi, T. Inoue, and Y. Katsuoka, “AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases,” Therapeutic Apheresis and Dialysis, vol. 11, no. 3, pp. 189–195, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. N. Yorioka, T. Ito, T. Masaki et al., “Dose-independent effect of an oral adsorbent, AST-120, in patients with early chronic renal failure,” Journal of International Medical Research, vol. 30, no. 5, pp. 467–475, 2002. View at Google Scholar · View at Scopus
  57. A. Owada, M. Nakao, J. Koike, K. Ujiie, K. Tomita, and T. Shiigai, “Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study,” Kidney International, Supplement, vol. 51, no. 63, pp. S188–S190, 1997. View at Google Scholar · View at Scopus